Cellcom Israel Ltd. (NYSE: CEL) (TASE: CEL) (the "Company") announced that it has published a shelf prospectus, after having received the Israeli Securities Authority, or ISA, and the Tel Aviv Stock Exchange, or TASE, approvals. The shelf …
Including today's unusual volume, CEL-SCI Corporation's stock is performing at …
The value of the position overall is down by 2.3%. On July 26, 2017 the stock rating was changed to a “Sell” in a report from Citigroup which was a cut from the previous “” rating. The company is now up from yesterday’s close of $8.41.
(AP) _ Cel-Sci Corp. (CVM) on Wednesday reported a loss of $4.4 million ... using data from Zacks Investment Research. Access a Zacks stock report on CVM at https://www.zacks.com/ap/CVM
CNBC11d
StockMarketWire.com - Ergomed said it has noted that its co-development partner CEL-SCI has confirmed the US Food and Drug Administration (FDA) has removed the clinical hold on the current Phase 3 study with Multikine in head and …
For the week, the stock is performing 30.43%. CEL-SCI has a 52-week low of $1.46 and a 52-week high of $3.69. It beta stands at -1.64. Shareholders can make better decisions if they focus on target prices, which convey more information …
Second Quarter 2017 Financial Results Recent Highlights Axicabtagene Ciloleucel (axi-cel) Regulatory and Clinical Development ... These adjustments to GAAP net loss exclude non-cash stock-based compensation expense. Kite …
Analysts reviewing Cel-Sci Corporation have recently updated their recommended buy/sell ratings and price targets on the stock. Ratings and price target breakdown: 03/04/2015 – Cel-Sci Corporation was upgraded to “” by analysts at Zacks. …
CEL-SCI’s share price leapt a quarter in morning trading on the New York Stock